Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.
Ohlsson, Sophie LU
; Bakoush, Omran
LU
; Tencer, Jan
LU
; Torffvit, Ole
LU
and Segelmark, Mårten
LU
(2009)
In Mediators of Inflammation
2009(Jul 5).
- Abstract
- BACKGROUND: The (anti neutrophil cytoplasmatic autoantibody ANCA), associated small vessel vasculitides (ASVV) are relapsing-remitting inflammatory disorders, involving various organs, such as the kidneys. (Monocyte chemoattractant protein 1 MCP-1) has been shown to be locally up regulated in glomerulonephritis and recent studies have pointed out MCP-1 as a promising marker of renal inflammation. Here we measure urinary cytokine levels in different phases of disease, exploring the possible prognostic value of MCP-1, together with (interleukin 6 IL-6), (interleukin 8 IL-8) and (immunoglobulin M IgM). METHODS: MCP-1, IL-6 and IL-8 were measured using commercially available ELISA kits, whereas IgM in the urine was measured by an in-house... (More)
- BACKGROUND: The (anti neutrophil cytoplasmatic autoantibody ANCA), associated small vessel vasculitides (ASVV) are relapsing-remitting inflammatory disorders, involving various organs, such as the kidneys. (Monocyte chemoattractant protein 1 MCP-1) has been shown to be locally up regulated in glomerulonephritis and recent studies have pointed out MCP-1 as a promising marker of renal inflammation. Here we measure urinary cytokine levels in different phases of disease, exploring the possible prognostic value of MCP-1, together with (interleukin 6 IL-6), (interleukin 8 IL-8) and (immunoglobulin M IgM). METHODS: MCP-1, IL-6 and IL-8 were measured using commercially available ELISA kits, whereas IgM in the urine was measured by an in-house ELISA. RESULTS: The MCP-1 levels in urine were significantly higher in patients in stable phase of the disease, compared with healthy controls. Patients in stable phase, with subsequent adverse events; had significantly higher MCP-1 values than patients who did not. MCP-1 and IgM both tended to be higher in patients relapsing within three months, an observation, however, not reaching statistical significance. Urinary levels of IL-6 correlated with relapse tendency, and IL-8 was associated with disease outcome. CONCLUSIONS: Patients with ASVV have raised cytokine levels in the urine compared to healthy controls, even during remission. Raised MCP-1 levels are associated with poor prognosis and possibly also with relapse tendency. The association with poor prognosis was stronger for U-MCP-1 than for conventional markers of disease like CRP, BVAS, and ANCA, as well as compared to candidate markers like U-IgM and U-IL-8. We thus consider U-MCP-1 to have promising potential as a prognostic marker in ASVV. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1453242
- author
- Ohlsson, Sophie
LU
; Bakoush, Omran
LU
; Tencer, Jan
LU
; Torffvit, Ole
LU
and Segelmark, Mårten
LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Mediators of Inflammation
- volume
- 2009
- issue
- Jul 5
- article number
- 584916
- publisher
- Hindawi Limited
- external identifiers
-
- wos:000268135800001
- pmid:19587833
- scopus:68949122734
- pmid:19587833
- ISSN
- 0962-9351
- DOI
- 10.1155/2009/584916
- language
- English
- LU publication?
- yes
- id
- 11c8678c-05db-4a16-8966-31b6abfc4c54 (old id 1453242)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/19587833?dopt=Abstract
- date added to LUP
- 2016-04-04 07:10:46
- date last changed
- 2024-02-10 19:02:31
@article{11c8678c-05db-4a16-8966-31b6abfc4c54,
abstract = {{BACKGROUND: The (anti neutrophil cytoplasmatic autoantibody ANCA), associated small vessel vasculitides (ASVV) are relapsing-remitting inflammatory disorders, involving various organs, such as the kidneys. (Monocyte chemoattractant protein 1 MCP-1) has been shown to be locally up regulated in glomerulonephritis and recent studies have pointed out MCP-1 as a promising marker of renal inflammation. Here we measure urinary cytokine levels in different phases of disease, exploring the possible prognostic value of MCP-1, together with (interleukin 6 IL-6), (interleukin 8 IL-8) and (immunoglobulin M IgM). METHODS: MCP-1, IL-6 and IL-8 were measured using commercially available ELISA kits, whereas IgM in the urine was measured by an in-house ELISA. RESULTS: The MCP-1 levels in urine were significantly higher in patients in stable phase of the disease, compared with healthy controls. Patients in stable phase, with subsequent adverse events; had significantly higher MCP-1 values than patients who did not. MCP-1 and IgM both tended to be higher in patients relapsing within three months, an observation, however, not reaching statistical significance. Urinary levels of IL-6 correlated with relapse tendency, and IL-8 was associated with disease outcome. CONCLUSIONS: Patients with ASVV have raised cytokine levels in the urine compared to healthy controls, even during remission. Raised MCP-1 levels are associated with poor prognosis and possibly also with relapse tendency. The association with poor prognosis was stronger for U-MCP-1 than for conventional markers of disease like CRP, BVAS, and ANCA, as well as compared to candidate markers like U-IgM and U-IL-8. We thus consider U-MCP-1 to have promising potential as a prognostic marker in ASVV.}},
author = {{Ohlsson, Sophie and Bakoush, Omran and Tencer, Jan and Torffvit, Ole and Segelmark, Mårten}},
issn = {{0962-9351}},
language = {{eng}},
number = {{Jul 5}},
publisher = {{Hindawi Limited}},
series = {{Mediators of Inflammation}},
title = {{Monocyte chemoattractant protein 1 is a prognostic marker in ANCA-associated small vessel vasculitis.}},
url = {{http://dx.doi.org/10.1155/2009/584916}},
doi = {{10.1155/2009/584916}},
volume = {{2009}},
year = {{2009}},
}